EU GMP Annex 11 Compliance
European requirements for computerized systems in GMP environments. BioWise is designed to meet these standards.
What is EU GMP Annex 11?
Annex 11 of the EU Guidelines for Good Manufacturing Practice is the European regulatory framework for computerized systems used in pharmaceutical manufacturing. It applies to all systems that support GMP-regulated activities, from laboratory systems to enterprise quality management.
The guideline emphasizes risk management, supplier assessment, and lifecycle management of computerized systems. It requires companies to demonstrate that systems are fit for purpose and maintained in a validated state throughout their operational life.
Key Requirements & How BioWise Complies
Risk Management (Clause 1)
Risk management should be applied throughout the lifecycle of the computerized system.
BioWise Implementation:
- • GAMP 5 risk-based approach documentation
- • Built-in risk assessment templates
- • Configurable validation scope based on system criticality
- • Continuous risk monitoring through audit trails
Personnel (Clause 2)
There should be close cooperation between all relevant personnel with defined responsibilities.
BioWise Implementation:
- • Role-based access reflecting organizational responsibilities
- • Training record integration capabilities
- • Clear system administration and QA roles
- • Comprehensive user documentation and training materials
Suppliers and Service Providers (Clause 3)
Suppliers should be assessed based on ability to provide quality systems.
BioWise Provides:
- • Quality Management System (ISO 9001 aligned)
- • Vendor audit support and facility access
- • Detailed technical and quality agreements
- • Transparent development and release processes
Validation (Clause 4)
Documentation should demonstrate fitness for purpose with evidence of system testing.
BioWise Support:
- • Complete IQ/OQ documentation packages
- • User Requirements Specification templates
- • Pre-defined test scripts
- • Validation summary report templates
Data (Clause 5-9)
Data must be protected, accurate, complete, and available throughout retention period.
BioWise Implementation:
- • Built-in data integrity controls (ALCOA+ compliant)
- • Automated backup and disaster recovery
- • Data archival with full retrieval capability
- • Printouts include audit trail information
Security (Clause 12)
Physical and/or logical controls to restrict access to authorized persons.
BioWise Implementation:
- • Enterprise-grade encryption (TLS 1.3, AES-256)
- • Multi-factor authentication
- • Session timeout and lockout policies
- • Comprehensive access logging
Annex 11 vs. 21 CFR Part 11
While both regulations address computerized systems in pharmaceutical environments, they have different focuses:
| Aspect | EU GMP Annex 11 | 21 CFR Part 11 |
|---|---|---|
| Focus | System lifecycle & risk management | Electronic records & signatures |
| Approach | Principles-based | Prescriptive requirements |
| Supplier emphasis | Strong (dedicated section) | Limited |
| Cloud guidance | Yes (Q&A document) | Limited |
BioWise is designed to meet both regulations. Our compliance architecture addresses the requirements of both FDA and EMA guidelines, enabling global pharmaceutical operations.
Questions about EU compliance?
Our team has extensive experience with EU GMP inspections and can help you understand how BioWise supports your compliance needs.
Request Demo